Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Decreased by Sanibel Captiva Trust Company Inc.

Sanibel Captiva Trust Company Inc. lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 77.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,556 shares of the medical research company’s stock after selling 19,244 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in Charles River Laboratories International were worth $1,026,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of Charles River Laboratories International in the third quarter valued at $601,000. JPMorgan Chase & Co. lifted its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares in the last quarter. State Street Corp boosted its position in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the period. Janus Henderson Group PLC grew its stake in Charles River Laboratories International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at about $966,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the subject of several research reports. TD Cowen raised their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Bank of America dropped their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Redburn Atlantic began coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price on the stock. Finally, CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $163.77 on Friday. The firm has a market capitalization of $8.37 billion, a PE ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $160.85 and a 1 year high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The firm’s fifty day simple moving average is $190.64 and its 200 day simple moving average is $198.42.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the business posted $2.72 earnings per share. The firm’s revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).